There’s something electric about watching a company live up to its name. Electra Therapeutics just closed a $183M Series C that crackled through the biotech world like a live wire. Co-led by Nextech and EQT Life Sciences, with new muscle from Sanofi, HBM Healthcare Investments, and Mubadala Capital, this round isn’t just capital, it’s current. The kind that moves an idea from the lab bench to a lifeline.
Founded in 2018 as the first spinout from Star Therapeutics, Electra has built its own orbit around a single obsession: targeting the immune system’s most destructive impulses before they burn the body down. CEO Kathy Dong, PharmD, MBA, isn’t chasing trends, she’s chasing diseases most people can’t even pronounce. She took Electra from stealth to spotlight with the kind of precision you only get from launching SOVALDI and HARVONI at Gilead, two of the biggest drugs in pharma history. Co-founder Adam Rosenthal, PhD, the brain behind Star Therapeutics and the architect of Electra’s origin, brings the kind of biotech street cred you can’t fake, MIT, Harvard, and a résumé that’s been acquired by Bristol Myers Squibb and Bioverativ for a combined $1.5B.
The Series C fuels the pivotal SURPASS study of ELA026, Electra’s first-in-class antibody designed to silence the cytokine storm behind secondary hemophagocytic lymphohistiocytosis (sHLH), a rare, often fatal hyperinflammatory condition with zero FDA-approved therapies. The early data isn’t whispering promise, it’s shouting it: 100% response at 4 weeks, 100% survival at 8 weeks, 100% hospital discharge. Numbers that make even veteran immunologists double-take.
ELA026 just snagged both FDA Breakthrough Therapy and EMA PRIME designations, marking the first therapy ever to earn both for sHLH. It’s biotech’s version of a standing ovation. Behind it all, Chief Scientific Officer Graham Parry, PhD, and Chief Medical Officer Kim-Hien Dao, DO, PhD, are quietly building an engine that could rewrite how immune dysfunction is treated across cancer, inflammation, and beyond.
But Electra isn’t stopping with one molecule. The Series C also powers ELA822, the company’s second SIRP-targeted program aimed at selectively depleting overactive T cells. Translation: the same tech that can tame runaway inflammation might soon tackle autoimmune disorders like Type 1 diabetes or multiple sclerosis. That’s not just diversification, it’s strategic dominance.
So, yes, $183M is a big headline. But the real story is what it powers: a company unafraid to go where Big Pharma hesitates. A leadership team proving that innovation doesn’t come from playing safe, it comes from understanding the system well enough to disrupt it from within.
